FASORACETAM


Synonyms	AEVI-001 AEVI001 Aevi-001 Fasoracetam LAM-105 LAM-105 ANHYDROUS LAM105 ANHYDROUS NFC-1 ANHYDROUS NFC1 ANHYDROUS NS-105 NS105
Status
Molecule Category	UNKNOWN
UNII	42O8UF5CJB
EPA CompTox	DTXSID9048855


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GOWRRBABHQUJMX-MRVPVSSYSA-N
Smiles	O=C1CC[C@H](C(=O)N2CCCCC2)N1
InChI	InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H16N2O2
Molecular Weight	196.25
AlogP	0.28
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	49.41
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	14.0

Related Entries

Cross References

Resources	Reference
ChEBI	31592
ChEMBL	CHEMBL2106179
DrugBank	DB16163
FDA SRS	42O8UF5CJB
KEGG	C13311
PubChem	198695
SureChEMBL	SCHEMBL194770
ZINC	ZINC000003779713

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).